Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Patents(United States)
- Current Assignee / Owner
- OTSUKA AMERICA PHARMA INC
- Publication Date
- 2017-12-12
Smart Images
Figure 1
Abstract
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is the National Stage Entry under 35 U.S.C. §371 of International Application No. PCT / US2014 / 069401 filed Dec. 9, 2014, which claims priority to U.S. Provisional Application No. 61 / 913,886 filed Dec. 9, 2013, the contents of both of which are hereby incorporated by reference.BACKGROUND
[0002] Fragile X-associated disorders are a family of genetic conditions that may affect individuals in a variety of ways. The three fragile X-associated disorders are fragile X syndrome (FXS), fragile X-associated tremor / ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI). The conditions are all caused by changes in the fragile X mental retardation 1 (FMR1) gene, located on the X chromosome. In most people, the FMR1 gene contains approximately 5-44 repeats of the cytosine guanine guanine (CGG) trinucleotide within the 5′ untranslated region.
[0003] Fragile X syndrome (FXS) is the most common inherited form o...